Immunotherapy | Tumor

CURE’s immunotherapy page features the latest cancer news and updates on immunotherapy Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in immunotherapy.

Injectable Tecentriq Is Efficacious, Reduces Treatment Time for Lung Cancer

August 2nd 2022

Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.

In Recent Decades, Immunotherapy Extended Advanced Melanoma Survival from Months to Years

July 11th 2022

Thanks to the FDA approval of immunotherapy agents, the average survival for patients for stage 4 melanoma has drastically increased over the past 20 years, an expert explained.

FDA Approves Kymriah for Relapsed/Refractory Follicular Lymphoma

May 31st 2022

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Skin Cancer Diagnosis, Older Age May Be Associated With Increased Risk for Rare Skin Condition from Immunotherapy Treatment

April 19th 2022

Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.

Invading Cancer Cells With Immunotherapy Combinations

March 16th 2022

Recent research has demonstrated the ability of immunotherapy combinations to target advanced melanoma.

Immunotherapy Side Effects: ‘No Organ System Potentially Unaffected’

November 23rd 2021

Immunotherapy side effects are a different than those of chemotherapy and other cancer treatments. Patients should know when to seek emergency care and what to communicate to clinicians.

The 'Promise' of Precision Medicine: Making Incurable Cancers Into Chronic Diseases

October 1st 2021

One oncologist highlighted the knowledge base of the immunotherapy and targeted therapy and how they interact with cancer cells.

Further Evaluating Biomarkers May Help to Better Interpret Which Patients Are Eligible For Immunotherapy

September 29th 2021

Getting rid of the "blanket statement" and looking deeper into genetics may allow patients with cancer who are older than 60 years to become eligible for immunotherapy, highlighting the importance of further research on the topic.

The Impact of Immunotherapy

June 25th 2021

Thanks to ongoing research and clinical trials, it seems that there are always new immunotherapies emerging.

Bispecific Antibodies Wage a Two-Pronged Attack on Tumors

June 16th 2021

BiTE therapy could lead to better ways to target the immune system, while minimizing the chance of resistance.

Intralesional Therapies Help Bridge the Gap Between Improved Results and Less Toxicity

June 15th 2021

First immunotherapy, intralesional therapy, is making a comeback and producing durable remissions for a subgroup of patients with cancer.

Tecentriq Significantly Improves Survival Outcome in Patients with Early-Stage Non-Small Cell Lung Cancer

May 21st 2021

The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.

Immunotherapy Could 'Provide A Whole New Realm' For Patients with Myeloma

May 14th 2021

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.

Our Microbiome: A Reflection of Ourselves?

May 9th 2021

Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.

Follow Your Gut: Advances in Understanding Microbiomes Are Transforming Cancer Care

April 28th 2021

The gut microbiome plays an important role in how patients may respond to cancer treatments, and researchers are learning more about ways to alter it to benefit treatment outcomes.

Targeting a Specific Genetic Mutation May Change Treatment Landscape for Non-Small Cell Lung Cancer

April 21st 2021

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Cell-Based Therapies May ‘Level the Playing Field’ in Non-Small Cell Lung Cancer

April 20th 2021

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

Antibiotics With Keytruda May Affect Survival in Non-Small Cell Lung Cancer

April 15th 2021

Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.

Rozlytrek Shows Potential for Non-Small Cell Lung Cancer

March 26th 2021

Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.

Immunotherapy 101: What Patients Can Expect from CAR-T Cell Therapy

December 3rd 2020

Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.

Mortality From COVID-19 Increases in Patients Receiving Systemic Cancer Treatments

October 14th 2020

In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.

Gut Microbiome May Play an Important Role in Immunotherapy in the Future, But More Research is Needed

July 28th 2020

The microorganisms inside a patient's gastrointestinal tract may have a role to play in how immunotherapy can treat certain types of cancer.

Immunotherapy Use Not Associated with Increased Risk of Death in Patients with Cancer and COVID-19

July 22nd 2020

More than half of the patients (61%) admitted to either the hospital or ICU were discharged and 12% remained in the hospital. Nine patients had died by the time data collection was cut off for this study.

Exciting Treatment Harnesses the Immune System

July 6th 2020

Immunotherapy is a wonderful testament to the benefits that arise from our growing understanding of the incredibly intricate human immune system.

FDA Approvals of Immunotherapy Keep Coming, Even at This Challenging Moment

July 6th 2020

In the 2020 special issue of CURE on Immunotherapy, we take a look at how the field of immunotherapy continues to grow despite challenges from the COVID-19 pandemic.

Staying Informed and Empowered as A Patient with Cancer

July 5th 2020

Cutting-edge medical information and first-person accounts empower patients to evaluate immunotherapy as a treatment option, one organization attests.

Unleashing the Power Within Using Tumor-Infiltrating Lymphocyte Therapy

June 30th 2020

Across cancer types, a unique immune-stimulating treatment called tumor-infiltrating lymphocyte therapy produces durable remissions that could last for decades.

Identifying Opportunities of Treatment From RNA Expressions

June 25th 2020

A new tool analyzes patterns of RNA expressed from genes, pinpointing more patients with cancer who can benefit from immunotherapies and targeted drugs.

New Immunotherapy Combinations Look to Create Maximum Velocity in Immune Systems Response to Cancer

June 24th 2020

New immunotherapy combinations aim to turbocharge the immune system’s attack against cancer.

Good News For Rare Cancer Treatment, Keytruda Can Help

June 23rd 2020

Immunotherapy with Keytruda shows promise in advanced uncommon cancers in which new treatment options are needed.